Skip to main content

Advertisement

SpringerLink
Log in

Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

It remains to be fully clarified whether there is a relationship between uncontrolled dyslipidemia and decline in estimated glomerular filtration rate (eGFR) in the general population. Therefore, this study’s aim was to test the association of dyslipidemia with changes in eGFR in apparently healthy working men.

Methods

We retrospectively examined the annual medical check-up list of 14,510 male workers aged 20–60 years with eGFR ≥ 60 mL/min/1.73 m2 at baseline, and then evaluated the association of the changes in the check-up parameters with a decline in eGFR during the 5-year observation period.

Results

Mean age and eGFR were 38.5 years and 82.3 mL/min/1.73 m2 at baseline, respectively. Evaluated low-density lipoprotein cholesterol (LDL-C) (≥140 mg/dL) was a strong indicator of CKD development in participants (basal eGFR 60–90 mL/min/1.73 m2) without hypertension [odds ratio (95% confidence interval): 1.46 (1.12–1.90)] or diabetes mellitus (DM) [1.49 (1.23–1.82)]. When LDL-C normalized under 140 mg/dL during follow-up, the decline in eGFR was smaller in non-hypertensive participants [−5.9 (−14.4 to −0.9) vs −13.4 (−18.4 to −4.5) mL/min/1.73 m2, p < 0.05]. There was an inverse correlation between change of LDL-C and decline in eGFR (p for trend <0.001).

Conclusion

Increased LDL-C levels are associated with the development of incident CKD and eGFR decline in young to middle-aged working men without hypertension and/or DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Thomas G, Sehgai AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–73.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto Y, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006;48:383–91.

    Article  PubMed  Google Scholar 

  3. O’Seaghdha CM, Hwang SJ, Upadhyay A, Meigs JB, Fox CS. Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis. 2010;56:852–60.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.

    Article  CAS  PubMed  Google Scholar 

  5. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.

    Article  PubMed  Google Scholar 

  6. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.

    Article  CAS  PubMed  Google Scholar 

  7. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013; Suppl 3:259–305.

    Google Scholar 

  9. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.

    Article  CAS  PubMed  Google Scholar 

  10. D’Adamo E, Santoro N, Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Endocrinol Metab Clin N Am. 2009;38:549–63.

    Article  Google Scholar 

  11. Vrdoljak A, Ivkovic V, Karanovic S, Dika Z, Domislovic V, Dapic K, et al. Glomerular hyperfiltration as a risk factor for renal impairment and hypertension in apparently healthy subjects. J Hypertens. 2016;34(Suppl 2):e19.

    Article  Google Scholar 

  12. Moriya T, Tanaka S, Sone H, Ishibashi S, Matsunaga S, Ohashi Y, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. J Diabetes Complicat. 2016. doi:10.1016/j.jdiacomp.2016.06.020. Accessed 29 Jun 2016.

    Google Scholar 

  13. Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J. 2011;75:905–10.

    Article  CAS  PubMed  Google Scholar 

  14. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388:276–84.

    Article  PubMed  Google Scholar 

  15. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, et al. The seven countries study: 2289 deaths in 15 years. Prev Med. 1984;13:141–54.

    Article  CAS  PubMed  Google Scholar 

  17. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezemitibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid loweiring with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–54.

    Article  CAS  PubMed  Google Scholar 

  19. Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  CAS  PubMed  Google Scholar 

  20. Niculescu LS, Sanda GM, Sima AV. HDL inhibits endoplasmic reticulum stress by stimulating apoE and CETP secretion from lipid-loaded macrophages. Biochem Biophys Res Commun. 2013;434:173–8.

    Article  CAS  PubMed  Google Scholar 

  21. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nistala R, Whaley-Connel A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008;10:2047–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Nakano T, Ninomiya T, Sumiyoshi S, Onimaru M, Fujii H, Itabe H, et al. Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney Int. 2013;84:373–80.

    Article  CAS  PubMed  Google Scholar 

  24. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.

    Article  CAS  PubMed  Google Scholar 

  25. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.

    Article  CAS  PubMed  Google Scholar 

  26. Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild decline in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS ONE. 2014;9:e106778.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, et al. Plasma lipoproteins and apolopoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112:3058–65.

    Article  CAS  PubMed  Google Scholar 

  28. Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statin in prevention: an intervention trial evaluating rousuvastatin). Clin Ther. 2011;33:717–25.

    Article  CAS  PubMed  Google Scholar 

  29. Rahman M, Yang W, Akkina S, Alpher A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2014;9:1190–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y, et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study. Atherosclerosis. 2009;203:587–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all staffs at the Health Care Center in Central Japan Railway Company and at the Health Promotion Center in Yamaha Motor Co., Ltd., for supplying annual health check-up data.

Author information

Authors and Affiliations

  1. Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu, 807-8555, Japan

    Akihiro Kuma & Yutaka Otsuji

  2. Blood Purification Unit, Hamamatsu University Hospital, 1-20-1 Handayama, Higashi, Hamamatsu, 431-3125, Japan

    Akihiro Kuma & Akihiko Kato

  3. Health Care Center, Central Japan Railway Company, 68 Kurogane, Aoi, Shizuoka, 420-0851, Japan

    Akihiro Kuma, Masatoshi Kawashima & Kazuhiko Enta

  4. Health Promotion Center, Yamaha Motor Co., Ltd., 2500 Shingai, Iwata, 438-8501, Japan

    Bungo Uchino & Yoko Ochiai

  5. Kidney Center, University Hospital of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu, 807-8556, Japan

    Masahito Tamura

Authors
  1. Akihiro Kuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bungo Uchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoko Ochiai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masatoshi Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhiko Enta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masahito Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yutaka Otsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akihiko Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akihiro Kuma.

Ethics declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee (Hamamatsu University School of Medicine, approval number E15-289) at which the studies were conducted and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

We provided all individual participants a means to opt out in this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 2712 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuma, A., Uchino, B., Ochiai, Y. et al. Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men. Clin Exp Nephrol 22, 15–27 (2018). https://doi.org/10.1007/s10157-017-1407-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-017-1407-8

Keywords

Search

Navigation